CLM 022
Alternative Names: CLM-022Latest Information Update: 04 Jun 2025
At a glance
- Originator Celloram
- Developer Genfit
- Class Anti-inflammatories; Hepatoprotectants; Small molecules; Triterpenes
- Mechanism of Action Antioxidants; NLRP3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases; Liver disorders
Most Recent Events
- 04 Jun 2025 Pharmacodynamics data from a preclinical trial in Liver disorders presented at the 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2024)
- 24 Apr 2025 Genfit plans a first-in-human trial in liver disorders as early as end of 2026 or beginning of 2027
- 24 Apr 2025 Genfit plans a formulation development and first toxicological studies in liver disorders in 2025